ABOUT RESVINET FOUNDATIONRSV (Respiratory Syncytial Virus) infection is the second most important cause of death during infancy, especially in developing countries.
Since the inception of ReSViNET network in 2014, we have continuously been working to fulfil our Vision and Mission with the goal to decrease the global burden of RSV infection through the advancement of research; providing scientific input and involvement in clinical trials. ReSViNET Foundation is a financially and otherwise independent regulated entity. save the date - RSVVW 2019
Advances in RSV vaccine developmentApril 2018 - Advances in knowledge of the structural biology of the RSV surface fusion (F) glycoprotein have revolutionized RSV vaccine development by providing a new target for preventive interventions. It is explained in this video, which was made by Djonie Jacobsen; Nienke Mombarg and Charlotte Wiersma, students from De Streek school in Ede, The Netherlands.
ReSViNET is proud to announce new publication in Lancet Infectious Diseases
26 June 2018 - We are happy to share with you that our manuscript "The RSV Vaccine Landscape: Lessons from the Graveyard and Promising Candidates” has been published online in the Lancet Infectious Diseases.
The aim of the manuscript is to give a comprehensive overview of vaccine candidates in clinical development, including maternal vaccine candidates. We hope you will enjoy reading the manuscript and look forward to receiving any questions or feedback. www.ncbi.nlm.nih.gov/pubmed/29914800 Official Launch of the ReSViNET Foundation
ZEIST, THE NETHERLANDS, 15 May 2018 – Today, we proudly announce the Official Launch of the ReSViNET Foundation as a registered not-for-profit entity under Dutch law. After 4 years of building and shaping the network and months of preparation, the ReSViNET Foundation has officially been founded.
As a foundation ReSViNET is now a financially and otherwise independent regulated entity which represents a major milestone for the entire ReSViNET project. Since the inception of ReSViNET network in 2014, we have continuously been working to fulfil our Vision and Mission: to decrease the global burden of RSV infection through the advancement of research; providing scientific input; involvement in clinical trials; and organising conferences and offering platforms to share the latest developments and reports on groundbreaking studies and in this way helping to move the field forward. We are exceptionally proud to be the first official Respiratory Syncytial Virus (RSV) foundation and aim to foster global collaboration among ... Beautiful impression video - RSV Vaccines for the World conference 2017ReSViNET Global partners |
PAPER OF THE MONTHEpithelial HMGB1: a novel treatment target for RSV infection Rayavara K, Kurosky A, Stafford SJ, Garg NJ, Brasier AR, Garofalo RP, Hosakote YM The first epithelial molecular events upon infection define the size and direction of the inflammatory response, which ultimately defines disease in RSV infected patients. Rayavara and collegues shed a light on this complex process. Previously, this group showed that RSV promotes the release of high mobility group box 1 (HMGB1) by airway epithelial cells. HMGB1 is a nuclear protein, which becomes an alarmin after secretion to the extracellular space to induce an inflammatory response. In the current study they show, that HMGB1 forms a link between the infected respiratory epithelium and the response by immune cells. After RSV infection, HMGB1 is expressed by airway epithelial cells. This process is dependent on TLR4 and is mediated by the MAPK and NF-kB pathway. Blocking of TLR4 or the NF-kB pathway in AECs, decreases the expression of HMGB1. Next they show that HMGB1 stimulates primary immune cells, such as monocytes and macrophages, to produce inflammatory cytokines and chemokines. Blocking the HMGB1 pathway, under an umbrella of antiviral treatment, might limit immune pathology and thereby ameliorate the course of disease in children with RSV infection. |
